BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Du ZQ, Zhao JZ, Dong J, Bi JB, Ren YF, Zhang J, Khalid B, Wu Z, Lv Y, Zhang XF, Wu RQ. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study. World J Gastroenterol 2019; 25(28): 3798-3807 [PMID: 31391774 DOI: 10.3748/wjg.v25.i28.3798]
URL: https://www.wjgnet.com/1007-9327/full/v25/i28/3798.htm
Number Citing Articles
1
Xun Qiu, Fengqiang Gao, Kai Wang, Zhensheng Zhang, Chuxiao Shao, Xiao Xu. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?iLIVER 2022; 1(1): 55 doi: 10.1016/j.iliver.2022.03.003
2
Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Guang-Xiao Meng, Kai-Xuan Liu, Zi-Niu Ding, Jian-Guo Hong, Zhi-Qiang Chen, Zhao-Ru Dong, Tao Li. Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysisJournal of Clinical and Translational Hepatology 2022; 10(5): 835 doi: 10.14218/JCTH.2021.00257
3
Yikai Wang, Muqi Wang, Chenrui Liu, Wenjun Wang, Juanjuan Shi, Shuangsuo Dang. Aspirin Use and the Risk of Hepatocellular CarcinomaJournal of Clinical Gastroenterology 2022; 56(7): e293 doi: 10.1097/MCG.0000000000001693
4
Hongda Ding, Yingshi Zhang, Liang Zhao, Si Wu, Junpeng Liu, Caibin Wang, Tong Pei, Yang Su. What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysisPharmacological Research 2020; 157: 104825 doi: 10.1016/j.phrs.2020.104825
5
Tracey G. Simon, Andrew T. Chan. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular CarcinomaClinics in Liver Disease 2020; 24(4): 549 doi: 10.1016/j.cld.2020.06.002
6
Xueliang Zhou, Tengfei Zhang, Yali Sun, Chunwei Li, Xianfei Ding, Yanhui Zhu, Lifeng Li, Zhirui Fan. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular CarcinomaFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.764854
7
Regina Zi Hwei Tan, Ian Lockart, Christina Abdel Shaheed, Mark Danta. Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinomaAlimentary Pharmacology & Therapeutics 2021; 54(4): 356 doi: 10.1111/apt.16515
8
Wenfeng Zhu, Xiaowen Wang, Yun Lv, Haoqi Chen, Xiaolong Chen, Xuejiao Li, Shuguang Zhu, Zexin Lin, Genshu Wang. Comparison of long-term outcomes of splenectomy with periesophagogastric devascularization and transjugular intrahepatic portosystemic shunt in treating cirrhotic portal hypertension patients with recurrent variceal bleedingLangenbeck's Archives of Surgery 2023; 408(1) doi: 10.1007/s00423-023-02933-1
9
Mengshi Yi, Xi Feng, Wei Peng, Fei Teng, Youyin Tang, Zheyu Chen. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver diseaseEuropean Journal of Clinical Pharmacology 2022; 78(4): 647 doi: 10.1007/s00228-021-03247-1
10
Daniel Eckhardt, Georg F. Weber. Perioperative Medizin für die Allgemein- und Viszeralchirurgie2024; : 349 doi: 10.1007/978-3-662-64404-1_38
11
Pamela Czajka, Adam Przybyłkowski, Anna Nowak, Marek Postula, Marta Wolska, Dagmara Mirowska-Guzel, Anna Czlonkowska, Ceren Eyileten. Antiplatelet drugs and liver fibrosisPlatelets 2022; 33(2): 219 doi: 10.1080/09537104.2021.1883574
12
Yuwei Liu, Tianqi Ren, Xiaotong Xu, Jinglan Jin. Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studiesEuropean Journal of Cancer Prevention 2022; 31(1): 35 doi: 10.1097/CEJ.0000000000000663
13
Jin Lin Tan, Sandeep Sidhu-Brar, Richard Woodman, Mohamed Asif Chinnaratha. Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysisJournal of Gastrointestinal Cancer 2023; 54(2): 325 doi: 10.1007/s12029-022-00842-y
14
Jonathan Abdelmalak, Natassia Tan, Danny Con, Guy Eslick, Ammar Majeed, William Kemp, Stuart K. Roberts. The Effect of Aspirin Use on Incident Hepatocellular Carcinoma—An Updated Systematic Review and Meta-AnalysisCancers 2023; 15(13): 3518 doi: 10.3390/cancers15133518
15
Pierluigi Ramadori, Thomas Klag, Nisar Peter Malek, Mathias Heikenwalder. Platelets in chronic liver disease, from bench to bedsideJHEP Reports 2019; 1(6): 448 doi: 10.1016/j.jhepr.2019.10.001
16
Myung Ji Goh, Dong Hyun Sinn. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?Clinical and Molecular Hepatology 2022; 28(3): 380 doi: 10.3350/cmh.2021.0366
17
Taha Ahmed, Alla Y. Grigorian, Adrian W. Messerli. Management of Acute Coronary Syndrome in Patients with Liver CirrhosisAmerican Journal of Cardiovascular Drugs 2022; 22(1): 55 doi: 10.1007/s40256-021-00478-6
18
Shaodi Ma, Guangbo Qu, Chenyu Sun, Haixia Liu, Yuemeng Jiang, Ning Li, Birong Wu, Juan Gao, Linya Feng, Peng Xie, Weihang Xia, Na Hyun Kim, Scott Lowe, Rachel Bentley, Yike Zhu, Qin Zhou, Yehuan Sun. Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose–response meta-analysisEuropean Journal of Clinical Pharmacology 2023; 79(1): 39 doi: 10.1007/s00228-022-03414-y